Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure

This report provides the first detailed neuropathological study of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐induced parkinsonism in humans. All 3 subjects self‐administered the drug under the impression it was “synthetic heroin” and subsequently developed severe and unremitting parkinsoni...

Full description

Saved in:
Bibliographic Details
Published inAnnals of neurology Vol. 46; no. 4; pp. 598 - 605
Main Authors Langston, J. W., Forno, L. S., Tetrud, J., Reeves, A. G., Kaplan, J. A., Karluk, D.
Format Journal Article
LanguageEnglish
Published New York John Wiley & Sons, Inc 01.10.1999
Willey-Liss
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:This report provides the first detailed neuropathological study of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐induced parkinsonism in humans. All 3 subjects self‐administered the drug under the impression it was “synthetic heroin” and subsequently developed severe and unremitting parkinsonism, which was L‐dopa responsive, at least in the earlier stages of illness. Survival times ranged from 3 to 16 years. Neuropathological examination revealed moderate to severe depletion of pigmented nerve cells in the substantia nigra in each case. Lewy bodies were not present. In Patients 1 and 2, there was gliosis and clustering of microglia around nerve cells. Patient 3 had a similar picture and also showed large amounts of extraneuronal melanin. These findings are indicative of active, ongoing nerve cell loss, suggesting that a time‐limited insult to the nigrostriatal system can set in motion a self‐perpetuating process of neurodegeneration. Although the mechanism by which this occurs is far from clear, the precedent set by the cases could have broad implications for human neurodegenerative disease.
Bibliography:Parkinson's Institute
National Institutes of Health - No. RO1 AG09121
VA Medical Research Program
ark:/67375/WNG-PJ233NPK-9
National Parkinson's Foundation
ArticleID:ANA7
istex:88B7F529CE0D6A5D1492D669DE5B72A761FF9402
ISSN:0364-5134
1531-8249
DOI:10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F